JP2012500205A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500205A5
JP2012500205A5 JP2011523131A JP2011523131A JP2012500205A5 JP 2012500205 A5 JP2012500205 A5 JP 2012500205A5 JP 2011523131 A JP2011523131 A JP 2011523131A JP 2011523131 A JP2011523131 A JP 2011523131A JP 2012500205 A5 JP2012500205 A5 JP 2012500205A5
Authority
JP
Japan
Prior art keywords
alkoxy
alkylamino
heteroaryl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011523131A
Other languages
English (en)
Japanese (ja)
Other versions
JP5546540B2 (ja
JP2012500205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053524 external-priority patent/WO2010019646A1/en
Publication of JP2012500205A publication Critical patent/JP2012500205A/ja
Publication of JP2012500205A5 publication Critical patent/JP2012500205A5/ja
Application granted granted Critical
Publication of JP5546540B2 publication Critical patent/JP5546540B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011523131A 2008-08-12 2009-08-12 スフィンゴシン‐1‐リン酸(s1p)レセプター拮抗薬およびその使用方法 Expired - Fee Related JP5546540B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8821708P 2008-08-12 2008-08-12
US61/088,217 2008-08-12
PCT/US2009/053524 WO2010019646A1 (en) 2008-08-12 2009-08-12 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof

Publications (3)

Publication Number Publication Date
JP2012500205A JP2012500205A (ja) 2012-01-05
JP2012500205A5 true JP2012500205A5 (enExample) 2012-09-27
JP5546540B2 JP5546540B2 (ja) 2014-07-09

Family

ID=41165710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523131A Expired - Fee Related JP5546540B2 (ja) 2008-08-12 2009-08-12 スフィンゴシン‐1‐リン酸(s1p)レセプター拮抗薬およびその使用方法

Country Status (10)

Country Link
US (1) US8049037B2 (enExample)
EP (1) EP2328863A1 (enExample)
JP (1) JP5546540B2 (enExample)
KR (1) KR20110044893A (enExample)
CN (1) CN102119140B (enExample)
AU (1) AU2009282017B2 (enExample)
BR (1) BRPI0918399A2 (enExample)
CA (1) CA2733970A1 (enExample)
RU (1) RU2505527C2 (enExample)
WO (1) WO2010019646A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245174B (zh) 2008-10-17 2013-11-06 埃克塞利希斯股份有限公司 鞘氨醇-1-磷酸受体拮抗剂与抗微管剂之间的协同作用
US8168795B2 (en) * 2009-08-11 2012-05-01 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
WO2011028927A1 (en) * 2009-09-04 2011-03-10 Allergan, Inc. Selective sphingosine-1-phosphate receptor antagonists
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
KR101625872B1 (ko) 2015-01-27 2016-06-01 국민대학교산학협력단 스마트단말기의 이벤트 기반의 차량조명 제어시스템 및 그 제어방법, 그리고 이를 위한 컴퓨터로 판독가능한 기록매체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756062A (fr) * 1969-09-11 1971-03-11 Boehringer Sohn Ingelheim Derives de 1,1,1-trichlorethane leurs procedes de fabrication et leur utilisation en tant que substances biocides
JPS55111451A (en) 1979-02-19 1980-08-28 Nippon Kayaku Co Ltd Novel 2-hydroxybenzamide derivative and agricultural and horticultural soil bactericide
EP0146810A3 (de) 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US4659722A (en) * 1984-08-20 1987-04-21 Nippon Kayaku Kabushiki Kaisha Bactericidal N-(2,2,2 trichloroethyl)pyridinecarboxamides
JPS61172860A (ja) * 1985-01-28 1986-08-04 Nippon Kayaku Co Ltd 新規ピリジン誘導体及びそれを有効成分とする農園芸用細菌病防除剤
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
AU6310198A (en) 1997-03-12 1998-09-29 Takara Shuzo Co., Ltd. Sphingosine analogues
JP4091250B2 (ja) 1997-09-11 2008-05-28 タカラバイオ株式会社 スフィンゴシン類誘導体及び医薬組成物
AU5322399A (en) * 1998-07-27 2000-02-21 President And Fellows Of Harvard College Method of high-throughput screening of molecules and compounds for their effectson biological and chemical processes
CA2422044A1 (en) * 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
US7064217B2 (en) * 2001-01-30 2006-06-20 University Of Virginia Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
WO2002095361A2 (en) * 2001-05-22 2002-11-28 President And Fellows Of Harvard College Identification of anti-protozoal agents
JP4399253B2 (ja) 2001-06-20 2010-01-13 ワイス プラスミノゲンアクチベーターインヒビター−1(pai−1)のインヒビターとしての、置換されたインドール酸誘導体
GB0324210D0 (en) * 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0405289D0 (en) * 2004-03-09 2004-04-21 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2016528301A5 (enExample)
JP2013519675A5 (enExample)
HRP20150982T1 (hr) Novi modulatori sfingozin fosfat receptora
JP2012041349A5 (enExample)
JP2015501783A5 (enExample)
JP2010524932A5 (enExample)
HRP20151017T1 (hr) Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2012500205A5 (enExample)
JP2011528713A5 (enExample)
JP2009535352A5 (enExample)
JP2013542247A5 (enExample)
JP2016506960A5 (enExample)
IL202018A (en) 4,2-Difluoro-n- {2- (Methylaoxy) -5- [4- (4-Pyridazinyl) -6-Quinolinyl] -3-Pyridinyl} Benzenesulfonamide, its Pharmaceuticals and Its Use in the Treatment of Pi3 Kinase-Related Diseases
JP2012506872A5 (enExample)
JP2013537203A5 (enExample)
JP2013507439A5 (enExample)
JP2016534063A5 (enExample)
JP2011518833A5 (enExample)
JP2011527299A5 (enExample)
JP2019500387A5 (enExample)
JP2014505107A5 (enExample)
JP2013523733A5 (enExample)
JP2011516610A5 (enExample)
JP2015514781A5 (enExample)